Celon Pharma S.A. (WSE:CLN)
21.00
-0.10 (-0.47%)
May 27, 2026, 12:33 PM CET
Celon Pharma Revenue
Celon Pharma had revenue of 61.87M PLN in the quarter ending March 31, 2026, with 23.57% growth. This brings the company's revenue in the last twelve months to 226.35M, up 7.64% year-over-year. In the year 2024, Celon Pharma had annual revenue of 205.55M, down -4.25%.
Revenue (ttm)
226.35M
Revenue Growth
+7.64%
P/S Ratio
5.02
Revenue / Employee
399.91K
Employees
566
Market Cap
1.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 205.55M | -9.12M | -4.25% |
| Dec 31, 2023 | 214.66M | 20.78M | 10.72% |
| Dec 31, 2022 | 193.89M | -2.20M | -1.12% |
| Dec 31, 2021 | 196.09M | 38.64M | 24.54% |
| Dec 31, 2020 | 157.45M | 55.20M | 53.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NEUCA | 13.83B |
| Diagnostyka | 2.42B |
| Centrum Medyczne ENEL-MED | 854.27M |
| Synektik Spólka Akcyjna | 706.45M |
| Mercator Medical | 585.57M |
| Voxel | 583.79M |
| Selvita | 359.93M |
| Ryvu Therapeutics | 88.38M |
Celon Pharma News
- 6 days ago - Celon Pharma Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Celon Pharma Annual report: Q4 2025 - Filings
- 6 months ago - Celon Pharma Quarterly report: Q3 2025 - Filings
- 6 months ago - Celon Pharma Slides: Q3 2025 - Filings
- 8 months ago - Celon Pharma Quarterly report: Q2 2025 - Filings
- 8 months ago - Celon Pharma Slides: Q2 2025 - Filings
- 1 year ago - Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease - Benzinga